Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Olipudase Alfa→

Olipudase Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
927883-84-9
Molecular formula
C2900H4373N783O791S24
Molecular weight
63631.13 g/mol
Drug class
Recombinant human acid sphingomyelinaseenzyme replacement therapy biologic
Mechanism of action
Provides exogenous acid sphingomyelinase that hydrolyses sphingomyelin to ceramide and phosphorylcholine in lysosomes, reducing sphingomyelin accumulation in peripheral organs.
Indications / reported uses
  • Enzyme replacement therapy for non-central-nervous-system manifestations of acid sphingomyelinase deficiency (ASMD) in adults and paediatric patients; it does not treat CNS manifestations because the enzyme does not cross the blood-brain barrier

Sources: US DailyMed — XENPOZYME (olipudase alfa-rpcp) · EMA EPAR — Xenpozyme · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Olipudase Alfa Environmental Risk Assessment (ERA) (the Olipudase Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.